ARCELLX (ACLX)

$72.89 0.73 (1.00%)

20:00 EDT ACLX Stock Quote Delayed 30 Minutes

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024

By InvestorPlace Earnings Aug 9, 2024

ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

7 Biotech Stocks to Put on Your Breakthrough Radar

Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids

Volume:

Previous Close $72.48

Market Cap 3.98B

PE Ratio -36.37

EPS -2.0042

Volume (Avg. Vol.) 464,690

Day's Range $70.85 - $72.43

52-Week Range $47.88 - $107.37

Dividend & Yield N/A (N/A)

ACLX Stock Predictions, Articles, and ARCELLX News

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 9, 2024

ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine

By Jeremy Flint, InvestorPlace Contributor May 9, 2024

These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.

The 3 Biotech Stocks That Could Make Your February Unforgettable

By Ian Cooper, InvestorPlace Contributor Feb 15, 2024

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

By Jeremy Flint, InvestorPlace Contributor Jan 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development

By John Blankenhorn, InvestorPlace Contributor Dec 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

3 Biotech Stocks That Could Be Multibaggers in the Making

By Muslim Farooque, InvestorPlace Contributor Nov 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

7 Biotech Stocks to Get In Now Before Investors Catch On

By John Blankenhorn, InvestorPlace Contributor Oct 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs

By Larry Ramer, InvestorPlace Contributor Oct 2, 2023

CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 20, 2023

It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning!

Why Is Arcellx (ACLX) Stock Up 25% Today?

By David Moadel, InvestorPlace Contributor Dec 9, 2022

ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business.

ARCELLX (ACLX)

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

7 Biotech Stocks to Put on Your Breakthrough Radar

Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ARCELLX (ACLX)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ACLX Stock Predictions, Articles, and ARCELLX News

Subscriber Sign in